Defiance Daily Target 2x Long LMND ETF
Key Statistics
Historical Performance
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
Top 8 holdings as of Apr 30, 2026 · source: SEC N-PORT. Full holdings & prospectus →
About LMNX
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience.
LMNX News
- Antimicrobial Resistance Surveillance Market (2026-2031) - Rising Prevalence of Drug-Resistant Infections to Drive Growth
- Defiance ETFs Announces Closure of Select Funds
- Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) Short Interest Down 53.1% in July
- Data I/O Corp (DAIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% Sequentially, ...
- Nasdaq, Inc. (NDAQ) Stock: Rebounds as LeveL Markets Acquisition Targets Digital Liquidity Growth
- Nasdaq acquires LeveL Markets ATS in always-on markets push
- Nanomedicine Market Report Examines Products, Services and Growth Opportunities Through 2030
- Nasdaq Announces Definitive Agreement to Acquire LeveL Markets, Advancing Nasdaq’s Always-On Markets Strategy
- Reviewing Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Acutus Medical (NASDAQ:AFIB)
- Diasorin SpA (DSRLF) (H1 2026) Earnings Call Highlights: Return to Growth, Strong U.S. ...
- DCN Dx Names Trevor Brown Chief Revenue Officer
- Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) Short Interest Update
Data for LMNX is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.